Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.

Abstract: The present invention relates to a method for recombinant production of Labyrinthopeptins and functional derivatives thereof. Moreover, the present invention relates to novel functional derivatives of Labyrinthopeptins.

Abstract: The present invention relates to a method for the activation of silent genes in microorganisms by co-cultivation of an inducer and a recipient microorganism. The inducer is selected from a chemical inducer, a microorganism inducer which is selected from a killed microorganism cell and/or inactivated culture medium in which said microorganism cell had been cultured and/or medium inducer. The present invention furthermore relates to a method for screening for an inducer and to a method of screening for a recipient microorganism by co-cultivation of an inducer and a recipient organism. The methods are useful for the detection of medicaments, such as antibiotics. The present invention further relates to media for culturing microorganisms comprising an inducer.

Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.

Abstract: The invention relates to streptospirole derivatives of the general formula (I), wherein R1, R2, R3, X1, X2, Y1 and Y2 are as defined herein, a process for the preparation of said compounds by fermenting the microorganism Streptomyces sp. ST 108140 (DSM 19369) and optionally derivatizing the compounds produced by said microorganism, a pharmaceutical composition comprising at least one compound of the formula (I), and the use of a compound of the formula (I) for the preparation of a medicament for the treatment and/or prophylaxis of bacterial infections.

Abstract: The disclosure relates to a compound of the formula (I) wherein R1 is H, C(O)—(C1-C6)alkyl or C(O)—O—(C1-C6)alkyl; R2 is OH, NH2, NH—(C1-C6)alkyl, NH—(C1-C4)alkylene-phenyl or NH—(C1-C4)alkylene-pyridyl; R3 and R4 are independently of each other H or OH, or R3 and R4 together are ?O; and m and n are independently of one another 0, 1 or 2; in any stereochemical form, or a mixture of any stereochemical forms in any ratio, or a physiologically acceptable salt thereof, obtainable from Actinomadura namibiensis (DSM 6313), and its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.

Abstract: The invention relates to streptospirole derivatives of the general formula (I), wherein R1, R2, R3, X1, X2, Y1 and Y2 are as defined herein, a process for the preparation of said compounds by fermenting the microorganism Streptomyces sp. ST 108140 (DSM 19369) and optionally derivatizing the compounds produced by said microorganism, a pharmaceutical composition comprising at least one compound of the formula (I), and the use of a compound of the formula (I) for the preparation of a medicament for the treatment and/or prophylaxis of bacterial infections.

Abstract: The invention refers to so-called Labyrinthopeptin derivatives of the formula (I) wherein {A}, {B}, {C}, R1-R6, m and n are as defined herein, obtainable from microorganism strain Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, a pharmaceutical composition comprising it, prepro-Labyrinthopeptin, pro-Labyrinthopeptin, and DNA coding for prepro-Labyrinthopeptin and pro-Labyrinthopeptin.

Abstract: The invention relates to the use of a compound of the formula (I) for the treatment of bacterial infections caused by mycobacteria, nocardia or corynebacteria, wherein E is phosphorus; X1, X2 and X3 are oxygen; and R1 and R2 are as defined in the specification.

Abstract: The disclosure relates to a compound of the formula (I) wherein m and n are independently of one another 0, 1 or 2, obtainable from Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.

Abstract: The invention relates to the use of a compound of the formula (I) for the treatment of bacterial infections caused by mycobacteria and related microorganisms, such as tuberculosis, leprosy, nocardiosis, diphtheria, pulmonary mycobacterial infection, cutaneous mycobacterial infection, atypical mycobacterial infection and mycobacteriosis.

Abstract: The present invention relates to novel compounds, termed serpentemycins, of the formula (I) in which Y, R, R2, R3, R4, X, X2, X3, n, m and o are as defined in the specification, which are formed by the microorganism Actinomycetales sp. DSM 14865 during its fermentation, to chemical derivatives of the serpentemycins, to a process for preparing them, and to their use as pharmaceuticals, in particular for the treatment and prophylaxis of infectious bacterial diseases.

Abstract: Embodiments of the present invention relate to administering cephaibols to treat conditions of the nervous system and to treat those conditions in which suppressing the immune system would have beneficial effect.

Abstract: The present invention relates to novel active compounds named Citrullimycines, which are obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309), and to their pharmaceutically acceptable salts and derivatives. The present invention further relates to a process for the production of the Citrullimycines, to the microorganism Streptomycetes sp. ST 101396 (DSM 13309), to the use of the Citrullimycines and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, for example as inhibitors of the neurotensin receptor, and to pharmaceutical compositions comprising Citrullimycines or a pharmaceutically acceptable salt or derivative thereof.

Abstract: The present invention relates to the use of thiolutin dioxide and its derivatives in the manufacture of a medicament. Such medicaments are useful, for example, in the treatment of CNS disorders. The present invention also relates to a process for the production of thiolutin dioxide and its derivatives by fermentation of microorganisms, such as the microorganism Nocardiopsis species ST 100692 (DSM 13834).

Abstract: The invention relates to compounds of formula I in which R1, R2, E, X1, X2, and X3 have the meaning as described in the specification and claims, obtained by culturing Streptomyces species HAG 004107 (DSM 13381), and their physiologically tolerable salts and chemical equivalents. The invention furthermore relates to a process for the preparation of the cyclipostins, the microorganism HAG 004107 (DSM 13381), the use of the cyclipostins and their physiologically tolerable salts and chemical equivalents as pharmaceuticals, in particular as inhibitors of lipases, and pharmaceutical preparations which contain cyclipostin or a physiologically tolerable salt or equivalent thereof.

Abstract: The present invention relates to novel compounds, termed serpentemycins, of the formula (I) 1

Abstract: Embodiments of the present invention relate to administering cephaibols to treat conditions of the nervous system and to treat those conditions in which suppressing the immune system would have beneficial effect.

Abstract: The invention relates to a compound of formula (I) wherein R1 is a sugar; R2 is —CH2—O—(R7)m, R7 representing a sugar, or is —COOH; R3 is an epoxide-comprising group, or is C1-C6-alkyl or C2-C6-alkenyl, unsubstituted or substituted by at least one OH; R5 is H, C1-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl; R4R6, R8 and R10 independently of one another are H; C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, —X2H, or —X2R12, or R4 and R6 together and/or R8 and R10 together are =X2; X2 is O, NH, N—C1-C6-alkyl, N—C2-C6-alkenyl, N-C2-C6-alkynyl or S; R12 is C1-C6-alkyl, C2-C6—alkenyl, C2-C6-alkynyl, aryl or acyl; and m and n are 1 or 2; in any of its stereochemical forms and mixtures of these forms in any ratio, and a physiologically acceptable salt or derivative thereof. The compounds are obtainable from a culture of the microorganism Actinomycetales species HAG 003959, DSM 12931, by fermentation.

Abstract: The present invention relates to the use of thiolutin dioxide and its derivatives in the manufacture of a medicament. Such medicaments are useful, for example, in the treatment of CNS disorders. The present invention also relates to a process for the production of thiolutin dioxide and its derivatives by fermentation of microorganisms, such as the microorganism Nocardiopsis species ST 100692 (DSM 13834).